METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN ALPHA ESTROGEN RECEPTOR INHIBITOR

MX433674BActive Publication Date: 2026-05-19EISAI R&D MANAGEMENT CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: MX · MX
Patent Type: Patents
Current Assignee / Owner: EISAI R&D MANAGEMENT CO LTD
Filing Date: 2021-11-23
Publication Date: 2026-05-19

Application Information

Patent Timeline

23 Nov 2021

Application

19 May 2026

Publication

MX433674B

IPC: A61K31/4439; A61K9/20; A61K9/28; A61K9/48; A61K47/12; A61K47/26; A61K47/38; A61P35/00

CPC: A61K31/4439; A61K9/282; A61K9/2013; A61K9/2018; A61K9/2054; A61K9/2866; A61K9/4858; A61K9/4866

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Patent Text Reader

Abstract

The present invention relates to pharmaceutical compositions comprising a human ERA inhibitor and methods of cancer therapy using the ERA inhibitor. In particular, this document describes dosages of H3B-6545 with defined pharmacokinetic (PK) profiles that allow the inhibitor to be administered effectively and safely to a human subject in need thereof.

Need to check novelty before this filing date? Find Prior Art